

HY-P99682 · 1 mg
MedChemExpress · Cat: HY-P99682
Reach 3+ verified distributors
Manufacturer product page
medchemexpress.com/ladiratuzumab.html
Description
Ladiratuzumab hLIV22 is a humanized monoclonal antibody against zinc transporter LIV-1/ZIP6. Ladiratuzumab is conjugated to MMAE HY-15162 via a cleavable dipeptide linker to synthesize an antibody-drug conjugate ADC Ladiratuzumab vedotin HY-P99683 . Ladiratuzumab vedotin selectively targets LIV-1 protein overexpressed on the surface of tumor cells, enters cells through antibody-mediated receptor endocytosis, releases MMAE to inhibit microtubule polymerization, and kills adjacent tumor cells with a bystander effect. Ladiratuzumab can be used in the study of solid tumors such as metastatic triple-negative breast cancer mTNBC .